

LLS PedAL: The First-of-its-Kind Global Master Clinical Trial for Pediatric Acute Leukemia

What is LLS PedAL?

PedAL is the first-of-its-kind global master clinical trial for **Pediatric Acute Leukemia**. Led by The Leukemia & Lymphoma Society (LLS), LLS PedAL will fundamentally change how children with acute leukemia are treated replacing a one-size-fits-all chemotherapy with treatments tailored to each child's leukemia.

PedAL is the cornerstone of The Dare to Dream Project, that has an ambitious multi-year \$175 million fundraising goal over the next five years to fundamentally change treatment and care for children with blood cancer through advocacy, patient support, and research.

Why LLS PedAL?

PedAL strives to advance more effective, safer treatments with fewer long-term side effects that can have an impact on survivors for decades or even a lifetime.

- About 40% of children with acute myeloid leukemia (AML) will relapse from their treatment and many will not survive more than five years.
- Pediatric AML survivors can have long-term, often lifelong, complications from their cancer treatment.
- The survival rate for acute lymphoblastic leukemia (ALL), the most common type of pediatric blood cancer, is higher, but many of these children also suffer long-term effects from the harsh and outdated treatments.
- Some children with ALL stop responding to treatments, so new options are needed.

How will LLS PedAL work?

With multiple sites across the world brought together by global leaders in pediatric acute leukemia, PedAL will bring the dream of safer, more effective pediatric leukemia treatments closer to home for more families. There are several components of PedAL:

- **Screening trial:** The PedAL screening trial (COG Study APAL2020SC) will be available in the United States, Canada, Australia and New Zealand. The screening trial will identify the unique tumor biology of each child's cancer to help match them with the most promising treatment. Based on their tumor biology, families can choose to enroll eligible children in a PedAL therapeutic trial or any other trial that best meets their needs.
- **Therapeutic trials:** Through partnerships with the National Cancer Institute (NCI), part of the National Institutes of Health; Children's Oncology Group (COG); and the European Pediatric Acute Leukemia (EuPAL) Foundation, PedAL trials will be available to children and families worldwide. The PedAL Master Trial is designed to accommodate several treatment options so that researchers can investigate more than one drug at a time and see how well they work in treating relapsed acute leukemias. PedAL has the potential to stand as a model for future pediatric cancer clinical trials.

How will PedAL make finding clinical trials in pediatric acute leukemia easier?

With support from LLS, the University of Chicago's Pediatric Cancer Data Commons (PCDC), developed **GEARBOX (Genomic Eligibility Algorithm at Relapse for Better Outcomes)**, a unique search tool that will help healthcare professionals all over the world quickly match patients who have relapsed or refractory disease to appropriate clinical trials and lifesaving treatments. This platform will include clinical trials both within PedAL, as well as other trials

Transforming treatment and care for kids with blood cancer.

outside of PedAL for children with acute leukemia. GEARBOX will provide doctors with multiple trial options to help them make treatment decisions for their patients.

In addition, all families have access to LLS Clinical Trial Nurse Navigators, registered nurses with oncology training who are available throughout the entire clinical trial process, including sharing financial resources LLS provides that can help alleviate barriers. You can find out more at [this link](#).

How will PedAL Further Research Advancements?

By enrolling their child in the screening trial, parents are helping to advance research for all children because their child's tumor biology results will be assessed the same way as children around the globe to help researchers find patterns and to advance more targeted treatments worldwide. Led by the University of Chicago's Pediatric Cancer Data Commons (PCDC), the AML Data Commons will consolidate pediatric clinical trial data from multiple international institutions into a single, unified data set to ensure consistency in data collection, analysis and reporting. This will be the largest collection of data from children with leukemia available for researchers.

What makes PedAL unique?

PedAL is the first-of-its-kind global Master Clinical Trial for pediatric acute leukemia to be led by a nonprofit featuring a broad, global collaboration with industry leaders and academic institutions.

LLS has convened like-minded organizations from around the globe – including nonprofits such as NCI and COG, global foundations such as the EuPAL, based in the Netherlands, academic institutions such as the University of Chicago, and pharmaceutical companies to participate in this unprecedented effort.

PedAL will utilize investigator sites in the extensive COG network in the U.S., Canada, Australia and New Zealand, unique search tools created with the University of Chicago, investigational therapies from pharmaceutical companies, and the oversight of worldwide leaders in pediatric acute leukemia.

Why LLS?

LLS is a patient-focused nonprofit organization with a proven track record in leading master clinical trials. The Beat AML® Master Clinical Trial, launched in 2016, has shown that LLS is uniquely positioned to convene the right team of researchers and physicians, regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency, pharmaceutical and biotech partners, and patient groups to bring the promise of safer, more effective therapies to patients.

**KIDS ARE
DIFFERENT**

Finally their cancer treatment is, too.



Transforming treatment and care for kids with blood cancer.

Who's Who of PedAL Leadership Team

The PedAL Master Clinical Trial was conceived, developed and is being implemented under the direction of preeminent leaders in pediatric acute leukemia.



Gwen Nichols, MD
The Leukemia & Lymphoma Society
Co-Chair, LLS PedAL Initiative



Kimberly Stegmaier, MD
Dana-Farber Cancer Institute
Preclinical Discovery Lead



E. Anders Kolb, MD
Nemours Center for Cancer and Blood Disorders
Co-Chair, LLS PedAL Initiative



Samuel Volchenbom, MD, PhD
University of Chicago
Bioinformatics Lead



Soheil Meshinchi, MD, PhD
Fred Hutchinson Cancer Research Center
Target and Biomarker Lead



Laura Di Laurenzio, PhD
The Leukemia & Lymphoma Society
Project Leader



Todd Cooper, DO
Seattle Children's
Screening Trial Lead



Julie Guillot
AML Parent and Partnership Outreach Chair



Todd Alonzo, PhD
Children's Oncology Group
Group Statistician

